<DOC>
	<DOCNO>NCT01062152</DOCNO>
	<brief_summary>This open label , multicenter Phase 1 dose escalation study evaluate five dos ezatiostat combination lenalidomide patient non-del ( 5q ) low intermediate 1 risk MDS . The HI-E , HI-N , HI-P rate [ International Working Group ( IWG ) 2006 criterion ] safety treatment group evaluate select optimal dose ezatiostat combination lenalidomide future study .</brief_summary>
	<brief_title>Dose-Ranging Study Telintra® Tablets + Revlimid® Patients With Non-Deletion ( 5q ) Low Intermediate-1 Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Histologic diagnosis primary de novo MDS use WHO classification Nondel ( 5q ) low Intermediate1risk MDS ECOG performance status 01 Documented significant cytopenia least 2 month Must discontinue growth factor ( EPO , GCSF , GMCSF ) least 21 day prior study entry All study participant must register mandatory RevAssist® program willing able comply requirement RevAssist® Females childbearing potential two negative serum pregnancy test sensitivity least 50 mIU/mL . The first test perform within 1014 day , second test within 24 hour prescribe lenalidomide ( prescription must fill within seven day ) Known hypersensitivity Telintra™ ( intravenous oral ) Known prior therapy hypersensitivity thalidomide lenalidomide Prior allogenic bone marrow transplant MDS History prior malignancy Except treated carcinoma uterine cervix , basal cell squamous cell skin cancer , cancer ( e.g . breast , prostate ) patient diseasefree least 3 year . MDS evolving : A preexist myeloproliferative disorder An autoimmune disease Secondary prior treatment radiation chemotherapy History MDS IPSS score &gt; 1.0 Pregnant lactate woman Leptomeningeal leukemic meningitis Prior treatment DNA methyltransferase inhibitor ( DMTI ) [ e.g. , azacitadine , decitabine , etc . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hematology</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Low risk MDS</keyword>
	<keyword>Patients non-deletion ( 5q )</keyword>
	<keyword>Non-deletion 5q</keyword>
	<keyword>Non del ( 5q )</keyword>
	<keyword>Revlimid</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>Telintra</keyword>
	<keyword>ezatiostat hydrochloride</keyword>
	<keyword>ezatiostat</keyword>
	<keyword>TLK199</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Glutathione analog</keyword>
	<keyword>Glutathione Transferase</keyword>
	<keyword>Glutathione Transferase inhibitor</keyword>
	<keyword>Glutathione Transferase P1-1 inhibitor</keyword>
	<keyword>GSTp1-1 inhibitor</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Differentiation</keyword>
	<keyword>Enzyme inhibitor</keyword>
</DOC>